Thromboembolic events in COVID-19 ambulatory patients: An observational study about incidence, and thromboprophylaxis outcomes.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
06
2021
accepted:
06
06
2022
entrez:
4
8
2022
pubmed:
5
8
2022
medline:
9
8
2022
Statut:
epublish
Résumé
There are no clear data about the incidence and the prophylactic strategies of arterial and venous thromboembolic events (TE) in COVID-19 ambulatory patients. Thus, we conducted this study to analyze thromboembolic complications in this setting and to assess thromboprophylaxis management and outcomes in the real life. This is an observational study including Covid-19 ambulatory patients. We assessed incidence of venous and arterial TE events as well as thromboprophylaxis outcomes and hemorrhagic complications. We defined high risk thrombo-embolic factor according to the Belgian guidelines which are the only guidelines that described thromboprophylaxis in COVID-19 ambulatory patients. We included 2089 patients with a mean age of 43±16 years. The incidence of 30 days venous and arterial TE complications in our cohort was 1%. Venous thromboembolic complications occurred in 0.8% and arterial thromboembolic complications occurred in 0.3%.We noted at least one high-risk TE factor in 18.5% of patients but thromboprophylaxis was prescribed in 22.5% of the cases, LMWH in 18.1%, and Rivaroxaban in 3.7%. Hemorrhagic events occurred in eight patients (0.3%): five patients showed minor hemorrhagic events and three patients showed major ones (0.14%). Our study showed that the incidence of thromboembolic complications is very low in COVID-19 ambulatory patients. Paradoxically, there is an over prescription of thrombo-prophylaxis in this population.
Identifiants
pubmed: 35925930
doi: 10.1371/journal.pone.0270195
pii: PONE-D-21-20254
pmc: PMC9352084
doi:
Substances chimiques
Anticoagulants
0
Heparin, Low-Molecular-Weight
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0270195Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Thromb Res. 2020 Oct;194:116-118
pubmed: 32788102
Lancet. 2009 May 16;373(9676):1673-80
pubmed: 19411100
Acta Clin Belg. 2022 Apr;77(2):280-285
pubmed: 33012274
J Am Coll Cardiol. 2020 Nov 3;76(18):2060-2072
pubmed: 33121712
Thromb Res. 2021 Jun;202:17-23
pubmed: 33711754
Blood Adv. 2021 Feb 9;5(3):872-888
pubmed: 33560401
Angiology. 2019 Nov;70(10):896-907
pubmed: 31010298
JAMA. 2021 Apr 27;325(16):1613-1615
pubmed: 33734290
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619886022
pubmed: 31746218
Chest. 2020 Sep;158(3):1143-1163
pubmed: 32502594
Thromb Haemost. 2020 Dec;120(12):1597-1628
pubmed: 32920811
Res Pract Thromb Haemost. 2020 Oct 13;4(7):1178-1191
pubmed: 33043231
J Intern Med. 1992 Aug;232(2):155-60
pubmed: 1506812
Thromb Haemost. 2020 Jun;120(6):937-948
pubmed: 32316065
Thromb J. 2021 Jun 29;19(1):47
pubmed: 34187490
Prog Cardiovasc Dis. 2020 Jul-Aug;63(4):527-528
pubmed: 32389584
Blood. 2021 May 20;137(20):2838-2847
pubmed: 33824972
J Thromb Haemost. 2020 Jun;18(6):1421-1424
pubmed: 32271988
J Am Heart Assoc. 2014 Nov 17;3(6):e001152
pubmed: 25404191
JAMA. 2021 Nov 2;326(17):1703-1712
pubmed: 34633405
Res Pract Thromb Haemost. 2021 Feb 24;5(2):296-300
pubmed: 33733028
Cancer. 2013 Feb 1;119(3):648-55
pubmed: 22893596
Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):545-547
pubmed: 32990453
Am J Cardiovasc Drugs. 2020 Dec;20(6):525-533
pubmed: 32918208
J Thromb Thrombolysis. 2020 Jul;50(1):72-81
pubmed: 32440883
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448